Protein tyrosine phosphatases (PTPs), working with protein tyrosine kinases (PTKs), control the phosphorylation state of many proteins in the signal transduction pathways. HePTP is a tyrosine phosphatase expressed in hematopoietic cells and regulates the MAP kinases Erk and p38. It has been found that HePTP is often dysregualted in the preleukemic disorder myelodysplastic syndrome, as well as in acute myelogeneous leukemia. Small molecule inhibitors of HePTP will be useful as molecular probes for studying the mechanism of signal transduction and MAP kinase regulation, and may have therapeutic potential for the treatment of hematopoietic malignancies. This colorimetric HTS assay was developed and run to identify HePTP inhibitors. HePTP assay materials: 1) HePTP protein was provided by Dr. Mustelin (Sanford-Burnham Medical Research Institute, San Diego, CA). The pNPP pellets were obtained from Sigma-Aldrich (S0942). Biomol Green reagent was purchased from BIOMOL Research Laboratories, Inc (AK-111) 2) Assay Buffer: 50 mM Bis-Tris, pH 6.0, 2.5 mM DTT, 0.0125% Tween 20. 3) HePTP working solution contained 6.875 nM HePTP in assay buffer. Solution was prepared fresh prior to use. 4) pNPP working solution contained 1 mM pNPP in MQ water. Solution was prepared fresh prior to use. 5) Vanadate working solution - 45 mM Na3VO4 in 10% DMSO HePTP HTS protocol: 1) 4 uL of 100 uM compounds in 10% DMSO were dispensed in columns 3-24 of Greiner 384-well clear microtiter plates (781101). 2) 4 uL of the following solutions were using the Multidrop bulk dispenser (Thermo): a. 10% DMSO column 1 (negative control) b. 45 mM Na3VO4 in 10% DMSO - column 2 (positive control). 3) 8 uL of HePTP working solution was added to the whole plate using WellMate bulk dispenser (Matrix). 4) 8 uL of pNPP working solution was added to the whole plate using WellMate bulk dispenser (Matrix). 5) Final concentrations of the components in the assay were as follows: a. 20 mM Bis-Tris, pH 6.0, 1.0 mM DTT, 0.005% Tween 20. b. 2.75 nM HePTP (columns 1-24) c. 0.4 mM pNPP (columns 1-24) d. 9 mM Na3VO4 (column 2) e. 2 % DMSO (columns 1-24) f. 20 uM compounds (columns 3-24) 6) Plates were incubated for 1h at room temperature. 7) 40 uL of Biomol Green reagent was added to the entire plate using the WellMate bulk dispenser (Matrix). 8) Plates were incubated for 30 mins at room temperature 9) Absorbance at 620 nM was measured on the Envision plate reader (PerkinElmer). 10) Data analysis was performed using CBIS software (ChemInnovations, Inc). HePTP dose-response confirmation screening protocol: 1) Dose-response curves contained 10 concentrations of compounds obtained using 2-fold serial dilution. Compounds were serially diluted in 100% DMSO, and then diluted with water to 10% final DMSO concentration. 4 uL compounds in 10% DMSO were transferred into columns 3-22 of Greiner 384-well white small-volume plates (784075). Columns 1-2 and 23-24 contained 4 uL of vanadate working solution and 10% DMSO, respectively. 2) 8 uL of HePTP working solution was added to the whole plate using WellMate bulk dispenser (Matrix). 3) 8 uL of pNPP working solution was added to the whole plate using WellMate bulk dispenser (Matrix). 4) Plates were incubated for 1h at room temperature. 5) Absorbance at 620 nM was measured on the Envision plate reader (PerkinElmer).
bao:BAO_0001067 "521_2" ; # "is primary assay of" -> "521_2"
bao:BAO_0001067 "1059" ; # "is primary assay of" -> "1059"
bao:BAO_0001067 "1077" ; # "is primary assay of" -> "1077"
bao:BAO_0001067 "2068" ; # "is primary assay of" -> "2068"
bao:BAO_0001067 "2134" ; # "is primary assay of" -> "2134"
bao:BAO_0000812 "2085" ; # "has summary assay" -> "2085"
bao:BAO_0000808 bao:BAO_0000031 ; # "has primary assay" -> "primary assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000287 ; # "has participant" -> "hydrolase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 "hydrolase activity assay" ; # "is bioassay type of" -> "hydrolase activity assay"
bao:BAO_0000212 bao:BAO_0000124 ; # "has assay method" -> "enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0000139 ; # "has assay method" -> "direct enzyme activity measurement method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> bao:BAO_0000484 ; # "has assay design method" -> "enzyme inhibition"
bao:BAO_0000207 bao:BAO_0000070 ; # "has detection method" -> "absorbance"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "\"To discover of chemical inhibitors of HePTP, a leukemia target.\"" ; # "screening campaign name" -> ""To discover of chemical inhibitors of HePTP, a leukemia target.""
bao:BAO_0002853 "\"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target\"" ; # "has assay title" -> ""HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target""
bao:BAO_0002867 bao:BAO_0000515 ; # "has assay footprint" -> "384 well plate"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "1 hour" ; # "has incubation time value" -> "1 hour"
bao:BA0_0090012 "Na3VO4" ; # "has participant" -> "Na3VO4"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "4.5" ; # "positive control concentration" -> "4.5"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000063> ; # "has concentration unit" -> "millimolar"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Tomas Mustelin" ; # "material entity assay provider" -> "Tomas Mustelin" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000694 ; # "has participant" -> "Tris" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35225> ; # "has role" -> "buffer"
bao:BA0_0090012 bao:BAO_0001038 ; # "has participant" -> "Tween 20" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_27780> ; # "has role" -> "detergent"
bao:BAO_0002000 bao:BAO_0001018 ; # "has measured entity" -> "Sodium orthovanadate" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_35222> ; # "has role" -> "inhibitor"
bao:BA0_0090012 bao:BAO_0000895 ; # "has participant" -> "DTT" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_63247> ; # "has role" -> "reducing agent"
bao:BA0_0090012 "\"Para-nitrophenyl phosphate, pNPP\"" ; # "has participant" -> ""Para-nitrophenyl phosphate, pNPP"" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 "Tyrosine-protein phosphatase non-receptor type 7 isoform 2" ; # "has participant" -> "Tyrosine-protein phosphatase non-receptor type 7 isoform 2"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "5778" ; # "gene ID" -> "5778"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P35236-2" ; # "uniprot ID" -> "P35236-2"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "5778" ; # "construct gene ID" -> "5778"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0000986 ; # "has participant" -> "Para-nitrophenol"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0000648 bao:BAO_0000733 ; # "compound library" -> "MLSMR library"
bao:BAO_0000648 bao:BAO_0000735 ; # "compound library" -> "DIVERSet"
bao:BAO_0000737 bao:BAO_0000720 ; # "has manufacturer" -> "ChemBridge" || bao:BAO_0003102 bao:BAO_0002627 ; # "has role" -> "compound library manufacturer"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000568 "620 nanometer" ; # "absorbance wavelength" -> "620 nanometer"
bao:BAO_0000337 bao:BAO_0000201 ; # "has percent response" -> "percent inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "5" ; # "PubChem TID" -> "5"
bao:BAO_0000182 <http://purl.org/obo/owl/UO#UO_0000187> ; # "has response unit" -> "percent"
bao:BAO_0002666 "20" ; # "has concentration value" -> "20"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "kunie-2" ; # "Annotated by" -> "kunie-2"
bao:BAO_0000809 bao:BAO_0000030 ; # "has confirmatory assay" -> "confirmatory assay"
bao:BAO_0000208 bao:BAO_0000190 ; # "has endpoint" -> "IC50"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
